A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

NCT06732895 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Achondroplasia

Interventions

DRUG: Navepegritide
DRUG: Placebo for navepegritide

Sponsor

Ascendis Pharma A/S